SYNDAX PHARMACEUTICALS INC (SNDX)
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
📉 **NEGATIVE** • Low confidence analysis (49%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (23%) **Content type:** Clinical